Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Fokus Mining Intersects 10 Metres Grading 10.06 G/T At The Galloway Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News G1 Therapeutics Inc GTHX

Healthcare Biotechnology
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The Company's lead commercial product, COSELA (trilaciclib), is a therapy indicated to proactively help protect bone marrow (myeloprotection) from the damage of chemotherapy. Its product... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:GTHX)

G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024

GlobeNewswire 22 hours ago

G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire 13 days ago

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 1, 2024

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 1, 2024

G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

GlobeNewswire February 28, 2024

G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

GlobeNewswire February 27, 2024

G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024

GlobeNewswire February 15, 2024

G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee

GlobeNewswire February 12, 2024

G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 8, 2024
View More News ››

Opinion & Analysis (NDAQ:GTHX)

Analyst: G1 Minimizes the Carnage of Chemotherapy

Streetwise Reports July 2, 2020
View More Opinion ››

Bullboard Posts (NDAQ:GTHX)

G1 Therapeutics Provides Fourth Quarter and Full Year 2023 F

BREAKING NEWS: $GTHX G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights- Achieved...
whytestocks - February 28, 2024

$iMIN making moves in Ethereum Crypto !! 🚀🚀🚀🚀🚀

iMining Launches Fractional Staking to Enable Retail Investors to Participate in Ethereum 2.0's Proof-Of-Stake Mining Vancouver...
Saaaa1 - May 6, 2021
View more Bullboard ››

Permex Petroleum Corp

Permex Petroleum Corp

Permex Petroleum Corporation is a junior oil and gas company. The Company is engaged in the acquisition, exploration ...
View More »